Press release
COVID-19: HABITNU MEDICARE DIABETES PREVENTION PROGRAM SHIFTS FROM IN-PERSON TO REMOTE
CDC recognized HabitNu has been delivering both the online and in-person DPP since 2017. HabitNu DPP combines a digital version of the CDC curriculum with peer support and health coaching to help people make positive lifestyle changes. The program's group setting provides a supportive environment for individuals facing similar challenges and barriers to health and wellness to learn new skills, set and meet goals, and receive the community support they need to live happier healthier lives!HabitNu partners with pharmacies, fitness clubs and community health networks to deliver our in-person diabetes prevention program at partner organization locations in communities across the US, with partner organization staff as lifestyle coaches. In the past week, our coaches have noticed a drop off in participant attendance in our in-person classes as public awareness of Covid-19 pandemic increases and social distancing recommendations impact communities across the country. These participants are mostly seniors, often with preexisting health conditions and most vulnerable to anxiety, depression, loneliness, and stress.
HabitNu believes it is imperative to provide a semblance of normalcy in the lives of its members by continuing to deliver HabitNu DPP while keeping them connected to each other during these stressful times. HabitNu has instructed its coaches to shift all in-person classes to its online delivery platform to prevent interruption of the classes and the overall progress of our participants. Our goal is to have this transition completed by Monday, March 23. This shift to a virtual classroom will not be disruptive since most of our in-person participants use the HabitNu APP with its food diary, device connectivity and in-app messaging, and HabitNu Connect, our secure group chat portal through which individuals become part of a supportive community.
Our online DPP program will follow the recommendations provided in CDC's "Guidance for CDC-Recognized Organizations on Alternative Program Delivery Options" memo dated March 12, 2020. Our partners and coaches will be reaching out to all participants over the next week to inform them of the newly implemented changes in the delivery of the DPP program. If you are a HabitNu participant and need more information on classes at your particular location, please contact us at support@habitnu.com.
March 13, 2020
222, West Merchandise Mart Plaza, Chicago, IL, 60654
HabitNu is a scalable solution that provides platforms to administer scientifically proven programs to combat lifestyle diseases. HabitNu National Diabetes Prevention Program (DPP) is developed by the Centers for Disease Control (CDC) and is available in-person and online. HabitNu DPP is fully recognized based on outcomes by the CDC. For more information visit http://www.habitnu.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release COVID-19: HABITNU MEDICARE DIABETES PREVENTION PROGRAM SHIFTS FROM IN-PERSON TO REMOTE here
News-ID: 1969591 • Views: …
More Releases for DPP
Digital Product Passports (DPP) Market Trends and Innovations for 2025
The Digital Product Passports (DPP) market is rapidly evolving, driven by the increasing need for transparency and sustainability in product lifecycles. As consumers become more conscious of environmental impacts and demand greater accountability from brands, DPPs provide a comprehensive solution by offering detailed information about a product's origin, materials, and end-of-life options. This emerging technology encapsulates a wide range of applications across various industries, including textiles, iron and steel, batteries,…
Game-Changers in Diabetes: DPP-4 Inhibitors Market Insights
The Business Research Company recently released a comprehensive report on the Global Dipeptide Peptidase 4 Inhibitors Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry.
Ready to Dive into Something Exciting? Get…
DPP IV Inhibitors (DPP-4 Inhibitors) Market to Witness Huge Growth by 2029 | Ast …
The DPP IV Inhibitors (DPP-4 Inhibitors) research report combines vital data incorporating the competitive landscape, global, regional, and country-specific market size, market growth analysis, market share, recent developments, and market growth in segmentation. Furthermore, the DPP IV Inhibitors (DPP-4 Inhibitors) research report offers information and thoughtful facts like share, revenue, historical data, and global market share. It also highlights vital aspects like opportunities, driving, product scope, market overview, and driving…
Global DPP IV Inhibitor Market Research Report Forecast 2017 to 2021
Report Hive Market Research Released a New Research Report of 120 pages on Title " Global DPP IV Inhibitor Market Research Report Forecast 2017 to 2021 "with detailed Analysis, Forecast and Strategies.
The Global DPP IV Inhibitor Market Research Report Forecast 2017-2021 is a valuable source of insightful data for business strategists. It provides the DPP IV Inhibitor industry overview with growth analysis and historical & futuristic cost, revenue, demand and…
Global Dipeptidyl Peptidase-4 (DPP-4) Inhibitors Market Research Report 2017
Report Hive Market Research Released a New Research Report of 119 pages on Title " Global Dipeptidyl Peptidase-4 (DPP-4) Inhibitors Market Research Report 2017 "with detailed Analysis, Forecast and Strategies.
In this report, the global Dipeptidyl Peptidase-4 (DPP-4) Inhibitors market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.
Geographically,…
DPP IV Inhibitors Market Set to Surge Significantly by 2021
DPP IV inhibitors are a class of hypoglycemic agents that block the enzyme named dipeptidyl peptidase IV. Dipeptidyl peptidase IV enzyme break down the proteins that are responsible for stimulating the insulin producing cells that slows down gastric secretion. Proteins can activate the release of insulin and can control the blood sugar level if DPP IV is inhibited in our body. Moreover, DPP IV inhibitors restrict the formation of glucagon,…